ID: ALA4204376

Max Phase: Preclinical

Molecular Formula: C30H51FO2

Molecular Weight: 462.73

Molecule Type: Small molecule

Representations

Canonical SMILES:  C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@]2(C)C3=C(CC[C@]12C)[C@@]1(C)C[C@@H](F)[C@H](O)C(C)(C)[C@@H]1CC3

Standard InChI:  InChI=1S/C30H51FO2/c1-19(10-9-15-26(2,3)33)20-13-16-30(8)22-11-12-24-27(4,5)25(32)23(31)18-28(24,6)21(22)14-17-29(20,30)7/h19-20,23-25,32-33H,9-18H2,1-8H3/t19-,20-,23-,24+,25+,28-,29-,30+/m1/s1

Standard InChI Key:  UMSZQYXOBMKPGY-GEFITEMGSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 462.73

Molecular Weight (Monoisotopic): 462.3873

AlogP: 7.62

#Rotatable Bonds: 5

Polar Surface Area: 40.46

Molecular Species: NEUTRAL

HBA: 2

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 2

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 13.49

CX Basic pKa:

CX LogP: 6.46

CX LogD: 6.46

Aromatic Rings: 0

Heavy Atoms: 33

QED Weighted: 0.41

Np Likeness Score: 2.74

References

1. Yang X, Chen XJ, Yang Z, Xi YB, Wang L, Wu Y, Yan YB, Rao Y..  (2018)  Synthesis, Evaluation, and Structure-Activity Relationship Study of Lanosterol Derivatives To Reverse Mutant-Crystallin-Induced Protein Aggregation.,  61  (19): [PMID:30153006] [10.1021/acs.jmedchem.8b00705]

Source

Source(1):

• Scientific Literature